期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 212, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2020.113019
关键词
Non-small cell lung cancer (NSCLC); Epidermal growth factor receptor; L858R/T790M double mutants; Anti-proliferation; Anti-tumor efficacy in vivo
资金
- National Key Research and Development Project of China [2016YFA0602900]
- National Natural Science Foundation of China [21272280]
- Key Project of Guangdong Natural Science Foundation [2016A030311033]
- Guangdong Provincial Key Laboratory of Construction Foundation [2019B030301005]
- STPGC [201604020125]
- ISRTIPZC [2015-224]
A new series of EGFR (L858R/T790M) inhibitors were designed and synthesized, with compound 8l showing excellent anti-tumor activity, strong kinase inhibitory effect against EGFR double mutation, and low toxicity towards non-tumorigenic cells.
Lung cancer is the leading cause of cancer deaths. It has been demonstrated that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are efficacious in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). In this work, a new series of 2,4-diaryl pyrimidine derivatives containing cyclopropyl moiety were designed, synthesized and evaluated as novel selective EGFR(L858R/T790M) inhibitors. The most promising compound, 8l demonstrated excellent kinase inhibitory activity against EGFR double mutation with IC50 value of 0.26 nM. Moreover, 8l provided strong activity against H1975 cells with IC50 value of 0.008 mu M and exhibited little toxicity toward four non-tumorigenic cell lines. Furthermore, 8l showed potent anti-tumor efficacy in a murine EGFR(L858R/T790M)-driven H1975 xenograft model. These results indicated that 8l may be a promising drug candidate for further study. (C) 2020 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据